Context Therapeutics (NASDAQ:CNTX) Issues Earnings Results
Context Therapeutics (NASDAQ:CNTX – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.04), FiscalAI reports. Context Therapeutics Price Performance Shares of NASDAQ:CNTX traded up $0.14 during mid-day trading on Monday, hitting $3.02. The company had […]
Bionano Genomics (NASDAQ:BNGO) Posts Earnings Results, Beats Estimates By $0.78 EPS
Bionano Genomics (NASDAQ:BNGO – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.78, FiscalAI reports. The firm had revenue of ($20,528.49) million for the quarter, compared to analyst estimates of $7.88 million. Bionano Genomics had a negative return […]
Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Cabaletta Bio (NASDAQ:CABA – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05, FiscalAI reports. Cabaletta Bio Stock Down 3.3% Shares of NASDAQ CABA opened at $2.94 on Monday. The firm has a market cap of […]
Sutro Biopharma (NASDAQ:STRO) Issues Quarterly Earnings Results, Misses Expectations By $0.73 EPS
Sutro Biopharma (NASDAQ:STRO – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($5.39) EPS for the quarter, missing analysts’ consensus estimates of ($4.66) by ($0.73), FiscalAI reports. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The firm had revenue of $11.65 […]
Xilio Therapeutics (NASDAQ:XLO) Posts Quarterly Earnings Results, Beats Expectations By $2.49 EPS
Xilio Therapeutics (NASDAQ:XLO – Get Free Report) issued its quarterly earnings data on Monday. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.68) by $2.49, FiscalAI reports. The company had revenue of $13.69 million during the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics […]
last updated on 24 Mar 04:26